Impact of Non-ABL1 Mutations on Outcomes in Chronic Myeloid Leukemia

Akriti Jain, MD, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses her presentation from the 2024 American Society of Hematology Meeting and Exposition, where she presented findings on how non-ABL1 mutations influence outcomes for patients with chronic myeloid leukemia (CML).

With advancements enabling near-normal life expectancy for patients with CML, understanding factors impacting progression and treatment response remains vital. Retrospective data has revealed that mutations like ASXL1 and RUNX1 may affect progression rates to advanced disease stages, major molecular remission, and success in treatment-free remission.

Using next-generation sequencing, Jain highlights how the team analyzed patients in the chronic phase of CML to explore how such mutations impacted overall survival, event-free survival, and failure-free survival. These insights could guide personalized treatment strategies and improve long-term outcomes.

Transcription:

0:10 | We [were] presenting an abstract on impact of non-ABL1 mutations on outcomes in patients with chronic myeloid leukemia. As we know these days, patients with chronic myeloid leukemia have a life expectancy of normal individuals or people without cancer, so we are always trying to see what we can do to continue to improve these outcomes that we have for our patients [with CML]. And we have seen in small retrospective studies that non-ABL1 mutations like ASXL1 and RUNX1 can have an impact on rates of progression to blast phase or accelerated phase from chronic phase of CML. It can impact rates of major molecular response or major molecular remission, as well as the success of treatment-free remission.

1:00 | So, we wanted to see in our center, which is Cleveland Clinic, where we treat a lot of [patients with] CML in chronic phase, and we do have access to next generation sequencing through our in house laboratory, retrospectively, we wanted to look at patients that have had next generation sequencing or mutation testing done in chronic phase CML, if they had mutations, what impact that had on overall survival, event-free survival, and failure free survival.